Overview

Rifaximin in Patients With Diabetic Gastroparesis

Status:
Recruiting

Trial end date:
2021-09-14

Target enrollment:

Participant gender:

Summary

Researchers are trying to determine if subjects with diabetic gastroparesis and symptoms of bloating will have a greater improvement in bloating symptoms when treated with rifaximin.

Phase:

Phase 2

Details

Lead Sponsor:

Mayo Clinic

Treatments:

Rifaximin